FDA Brief

Warning letters Drugs

FDA warning letter to

Huons Co., Ltd.

High riskIssued Jun 15Posted Jun 23Center for Drug Evaluation and Research (CDER)

FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.

What happened

FDA inspected Huons' drug manufacturing facility in Jecheon, South Korea, from November 12 to 21, 2025. Investigators found manipulated and discarded microbiology test data, blank uncontrolled forms, fabricated logbook pages, inadequate investigations of failed test results, and poor airflow and glove controls on aseptic filling lines. The company suspended U.S. drug production and committed to a voluntary recall of all drugs made at the facility for the U.S. market.

What FDA found

  1. Laboratory records did not include complete original data; staff discarded bioburden plates with growth, manipulated camera timestamps, removed and fabricated logbook pages, and left an endotoxin failure undocumented.

    21 CFR 211.194(a)
  2. The company did not thoroughly investigate failed test results and used a passing retest to invalidate an original failure.

    21 CFR 211.192
  3. Smoke studies showed turbulent airflow and operators blocking first air in ISO 5 aseptic filling areas.

    21 CFR 211.113(b)
  4. Procedures for monitoring and cleaning gloves used in aseptic filling were inadequate and did not ensure all gloves were tested or frequently disinfected.

    21 CFR 211.42(c)(10)(vi)
  5. The quality unit lacked effective oversight and authority over laboratory and production operations.

    21 CFR 211.22

What FDA wants

FDA asks Huons to provide a comprehensive data integrity investigation and corrective action plan, an independent retrospective review of invalidated failed test results, contamination-hazard and environmental-monitoring assessments, and remediation timelines. It also asks the company to clarify whether it intends to resume U.S. drug manufacturing and to notify FDA before resuming; the letter does not state a response deadline.

Who should pay attention

  • U.S. buyers and distributors of Huons-made drugs
  • companies relying on microbiology or sterility data from contract manufacturers
  • sterile drug manufacturers and their quality units

This is a summary. Read the original letter on fda.gov.

Huons Co., Ltd.'s FDA history

Recalls in the last 12 months

Nov 4 Class II Huons Co., Ltd.
Drug
Carboxymethylcellulose Sodium, 0.5% Lubricant Eye Drops, Sterile, 30 Single-Use Containers, 0.02 FL OZ (0.5 mL) each, Manufactured by: Huons Co., Ltd, Jecheon-si, Chungcheongbuk-do, 27159, South Korea; Marketed by: GSMS …
Failed Impurities/Degradation Specification; detection of polyethylene (PE)-related oligomers
Apr 22 Class II Huons Co., Ltd.
Drug
0.9% Sodium Chloride Injection, USP, 10 mL Ampules, Rx only, Single Dose, Preservative Free, Manufactured for: Spectra Medical Devices, LLC, Wilmington, MA, 01887, By: Houns Co., Ltd, Jecheon, Korea, 27159, NDC 65282-151…
Lack of Assurance of Sterility
Apr 22 Class II Huons Co., Ltd.
Drug
Bupivacaine Hydrochloride 0.75% in 8.25% Dextrose Injection, USP (15 mg/2 mL) (7.5 mg/mL) ampules, Rx only, Manufactured by: Houns Co., Ltd, 100, Bio valley, Je-cheor-Si, Chungcheongbuk-dc, Korea, NDC 73293-0002-1 (2 mL …
Lack of Assurance of Sterility
Apr 22 Class II Huons Co., Ltd.
Drug
Lidocaine HCl injection, USP, 1% 50mg/5mL (10 mg/mL), 5 mL Single Dose Vials, Rx only, Manufactured by: Huons Co, Ltd, Chungcheongbuk-do, Korea NDC 73293-0001-1 (vial), NDC 73293-0001-2 (10 count carton); Distributed by:…
Lack of Assurance of Sterility
Apr 22 Class II Huons Co., Ltd.
Drug
Lidocaine HCl Injection, USP, 2%, 100 mg/5mL (20 mg/mL), 5 mL Single-Dose Vials, Rx only, Manufactured by: Huons Co., Ltd., 100 Bio valley-ro, Jecheon-si, Chungchengbuk-do, Korea, NDC 73293-0003-1 (vial), NDC 73293-0003-…
Lack of Assurance of Sterility

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk